Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–21. https://doi.org/10.1177/1352458520970841.
Article PubMed PubMed Central Google Scholar
Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26(1):27–40. https://doi.org/10.1111/ene.13819.
Article CAS PubMed Google Scholar
Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132–40. https://doi.org/10.1001/jamaneurol.2020.1568.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33:1444–52. https://doi.org/10.1212/wnl.33.11.1444.
Article CAS PubMed Google Scholar
Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int. 2014;2014: 262350. https://doi.org/10.1155/2014/262350.
Article PubMed PubMed Central Google Scholar
Braune S, Rossnagel F, Dikow H, Bergmann A, NeuroTransData Study Group. Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry. BMJ Open. 2021;11(8): e042480. https://doi.org/10.1136/bmjopen-2020-042480.
Article PubMed PubMed Central Google Scholar
Trisolini MA, Honeycutt A, Wiener J, Lesesne S. Global economic impact of multiple sclerosis. In: Multiple Sclerosis International Federation. 2010. https://www.msif.org/wp-content/uploads/2014/09/Global_economic_impact_of_MS.pdf. Accessed 13 Jul 2023.
Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, MSCOI Study Group; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–36. https://doi.org/10.1177/1352458517694432.
Article PubMed PubMed Central Google Scholar
Flachenecker P, Kobelt G, Berg J, Capsa D, Gannedahl M, European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Germany. Mult Scler. 2017;23(2_suppl):78–90. https://doi.org/10.1177/1352458517708141.
Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18(2 Suppl):7–15. https://doi.org/10.1177/1352458512441566.
Karampampa K, Gyllensten H, Yang F, et al. Healthcare, sickness absence, and disability pension cost trajectories in the first 5 years after diagnosis with multiple sclerosis: a prospective register-based cohort study in Sweden. Pharmacoecon Open. 2020;4(1):91–103. https://doi.org/10.1007/s41669-019-0150-3.
Ernstsson O, Gyllensten H, Alexanderson K, Tinghög P, Friberg E, Norlund A. Cost of illness of multiple sclerosis - a systematic review. PLoS ONE. 2016;11(7): e0159129. https://doi.org/10.1371/journal.pone.0159129.
Article CAS PubMed PubMed Central Google Scholar
Gyllensten H, Kavaliunas A, Murley C, et al. Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden. Mult Scler J Exp Transl Clin. 2019;5(2):2055217319858383. https://doi.org/10.1177/2055217319858383.
Article PubMed PubMed Central Google Scholar
Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990;40(6):971–5. https://doi.org/10.1212/wnl.40.6.971.
Article CAS PubMed Google Scholar
Cadavid D, Cohen JA, Freedman MS, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017;23(1):94–105. https://doi.org/10.1177/1352458516638941.
Meyer-Moock S, Feng Y-S, Maeurer M, Dippel F-W, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58. https://doi.org/10.1186/1471-2377-14-58.
Article PubMed PubMed Central Google Scholar
Mitchell AJ, Benito-León J, Morales González J-M, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 2005;4(9):556–66. https://doi.org/10.1016/S1474-4422(05)70166-6.
Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler. 2005;11(5):602–9. https://doi.org/10.1191/1352458505ms1204oa.
Cadden M, Arnett P. Factors associated with employment status in individuals with multiple sclerosis. Int J MS Care. 2015;17(6):284–91. https://doi.org/10.7224/1537-2073.2014-057.
Article PubMed PubMed Central Google Scholar
Oliva Ramirez A, Keenan A, Kalau O, Worthington E, Cohen L, Singh S. Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review. BMC Neurol. 2021;21(1):468. https://doi.org/10.1186/s12883-021-02396-1.
Article PubMed PubMed Central Google Scholar
Gustavsen S, Olsson A, Søndergaard HB, et al. The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey. BMC Neurol. 2021;21(1):317. https://doi.org/10.1186/s12883-021-02344-z.
Article CAS PubMed PubMed Central Google Scholar
Dillon P, Heer Y, Karamasioti E, et al. The socioeconomic impact of disability progression in multiple sclerosis: a retrospective cohort study of the German NeuroTransData (NTD) registry. Mult Scler J Exp Transl Clin. 2023;9(3):20552173231187810. https://doi.org/10.1177/20552173231187810.
Article PubMed PubMed Central Google Scholar
NeuroTransData GmbH. NTD database. 2022. https://www.neurotransdata.com/en/. Accessed 8 Apr 2022.
Smith A. Symbol digit modalities test. Los Angeles: Western Psychological Services; 1973.
D’Souza E. Modified Fatigue Impact Scale–5-item version (MFIS-5). Occup Med (Lond). 2016;66(3):256–7. https://doi.org/10.1093/occmed/kqv106.
Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for the nine hole peg test of finger dexterity. Occup Ther J Res. 1985;5(1):24–38. https://doi.org/10.1177/153944928500500102.
Bethoux FA, Palfy DM, Plow MA. Correlates of the timed 25 foot walk in a multiple sclerosis outpatient rehabilitation clinic. Int J Rehabil Res. 2016;39(2):134–9. https://doi.org/10.1097/MRR.0000000000000157.
Article PubMed PubMed Central Google Scholar
Bergmann A, Stangel M, Weih M, et al. Development of registry data to create interactive doctor-patient platforms for personalized patient care, taking the example of the DESTINY System. Front Digit Health. 2021;3: 633427. https://doi.org/10.3389/fdgth.2021.633427.
Article PubMed PubMed Central Google Scholar
Wehrle K, Tozzi V, Braune S, et al. Implementation of a data control framework to ensure confidentiality, integrity, and availability of high-quality real-world data (RWD) in the NeuroTransData (NTD) registry. JAMIA Open. 2022;5(1):ooac017. https://doi.org/10.1093/jamiaopen/ooac017.
Article PubMed PubMed Central Google Scholar
Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the EQ-5D-5L. Pharmacoeconomics. 2018;36(6):663–74. https://doi.org/10.1007/s40273-018-0615-8.
Comments (0)